About Baxtra
We discover, develop and deliver medicines for diseases where the current standard of care still leaves people waiting.
Our story
Founded on translational science
Baxtra began in 2011 in a converted laboratory on Binney Street with eleven scientists, a single protein-degradation platform and a conviction that most drug failures are failures of patient selection rather than of chemistry.
Fifteen years later that conviction is still the organising principle. Every Baxtra program must define, before it enters the clinic, the biomarker that identifies who will respond and the measurement that will show whether it worked.
We now operate research sites in Cambridge, San Diego, Basel, Cambridge (UK), Kobe and Bengaluru, and manufacture at two owned facilities in Ireland and North Carolina.
| Company at a glance | |
|---|---|
| Founded | 2011, Cambridge, Massachusetts |
| Headquarters | 1 Harborline Way, Cambridge, MA 02142 |
| Employees | 17,800 in 18 countries |
| R&D investment (2025) | $2.4 billion — 27% of revenue |
| Revenue (2025) | $8.9 billion |
| Approved medicines | 7 across 5 therapeutic areas |
| Active programs | 41 (9 in Phase 3 or registration) |
| Manufacturing sites | Dundalk, Ireland · Durham, North Carolina |
Purpose & values
What we hold ourselves to
Evidence over enthusiasm
We kill programs early when the data says so. In 2025 we discontinued five assets before Phase 2 — and said why.
Patients in the room
Patient advisory boards review every protocol before first-in-human dosing, including endpoint selection.
Access by design
Access strategy and pricing tiers are set at Phase 2, not after approval.
Open by default
Protocols, statistical analysis plans and redacted clinical study reports are posted for every registrational trial.
Leadership
Executive team
Dr. Amara Osei-Boateng
Chief Executive Officer
Molecular immunologist; joined Baxtra in 2014 to lead translational medicine and became CEO in 2021. Previously led inflammation research at a global biopharma.
Dr. Ines Marchetti
Chief Medical Officer
Nephrologist and clinical trialist. Oversees clinical development, pharmacovigilance and medical affairs across all therapeutic areas.
Dr. Lukas Brenner
President, Research
Chemical biologist who built the Baxtra degrader platform. Responsible for discovery through candidate selection.
Priya Raghunathan
Chief Financial Officer
Leads finance, corporate development and investor relations. Joined from a global diagnostics group in 2019.
Marcus Hale
Chief Technical Operations Officer
Runs manufacturing, quality and supply chain, including the Dundalk biologics facility.
Dr. Sun-Woo Park
Chief Data & Digital Officer
Leads the Baxtra genomics platform, real-world evidence and computational chemistry.
Elena Vasquez
General Counsel
Legal, compliance, ethics and global regulatory policy.
Tobias Lindqvist
Chief People Officer
Talent, culture, and the Baxtra Scientist Development Program.
Dr. Fatima Al-Rashid
Head of Global Access
Pricing, health economics and low- and middle-income country supply.
Locations
Where we work
| Site | Function | Colleagues |
|---|---|---|
| Cambridge, Massachusetts, USA | Global headquarters, discovery research, translational medicine | 3,900 |
| San Diego, California, USA | Protein degradation and structural biology | 1,150 |
| Durham, North Carolina, USA | Small molecule manufacturing and packaging | 2,300 |
| Basel, Switzerland | European headquarters, regulatory affairs | 1,600 |
| Cambridge, United Kingdom | Computational chemistry, genomics platform | 840 |
| Dundalk, Ireland | Biologics drug substance and fill-finish | 1,450 |
| Kobe, Japan | Clinical development, Asia-Pacific medical affairs | 720 |
| Bengaluru, India | Data sciences, pharmacovigilance operations | 2,100 |
| São Paulo, Brazil | Latin America commercial and access | 510 |
Work on medicines that matter
We are hiring across research, clinical development, manufacturing and data science.